References
Perumpail RB, Wong RJ, Ha LD, et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis. 2015;17:275–278.
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977 [Abstract]. In: Abstracts of the International Liver Congress 2012—47th Annual Meeting of the European Association for the Study of Liver, Barcelona, Spain, April 18–22, 2012.
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomized study. Lancet. 2014;384:1756–1765.
U.S. Food and Drug Administration. SOVALDI. 2013. http://www.accessdata.fda.gov/spl/data/b0de1fcd-6d03-4a91-a7df-72a14c8bc7d0/b0de1fcd-6d03-4a91-a7df-72a14c8bc7d0.xml. Accessed May 30, 2014.
U.S. Food and Drug Administration. OLYSIO. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf. Accessed May 30, 2014.
American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org/full-report-view. Accessed May 30, 2014.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perumpail, R.B., Wong, R.J., Pham, E.A. et al. A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis. Dig Dis Sci 61, 39–41 (2016). https://doi.org/10.1007/s10620-015-3756-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-015-3756-z